Strategic Priority 7: Regional engagement strategy to identify IA2030 global priority endemic pathogens

World Health Organization

Immunization, Vaccines and Biologicals
Vaccine Prioritization & Platforms Team

PDVAC, 12 December 2023

Goals and Outline

Goal: To present the global list of priority endemic pathogens for vaccine R&D

1. Rationale and anticipated change

2. Process and methodology

3. Results: What do stakeholders value?

4. Results: Global pathogen priorities

5. Support in developing regional R&D agendas

6. Monitoring

7. From analyses to actions

What is our goal?

World Health Organization

As a global health community, we must focus our efforts on developing vaccines for the pathogens that most impact communities across the world.

What?

- **Identify R&D priorities:** list of global endemic pathogen targets for new vaccines

Why?

- Because we want to develop vaccines that respond to regional and global needs

- Because we want to accelerate vaccine development by aligning immunization stakeholders

- Because we want to track progress in vaccine and immunization R&D under IA2030

How?

- **According to IA2030 Core Principles**

  - *People centered*: vaccines are developed to meet people's needs

  - *Data driven*: systematic and evidence-based approach to identify priorities

  - *Partnership based*: in partnership with regions and immunization stakeholders;

  - *Country owned*: countries and regions can translate vaccine priorities into local R&D strategies

- **With support from SP7 WG, PDVAC, and SAGE**

- Complementarity to other projects (Vaccines and AMR, R&D Blueprint)

3

How will the Global priority list be used?

World Health Organization

Priorities will **inform** stakeholder strategies
Priorities should be **considered** in the context of existing global, regional and country R&D strategies

Regional stakeholders

- **Industry**: inform vaccine R&D investments
- **Funders**: inform capacity building for vaccine R&D
- **Researchers**: inform evidence generation activities
- **Policy makers**: build awareness of R&D pipelines

Global stakeholders

- **WHO:** inform activities to accelerate evidence generation, R&D, and policy making to serve low-resource settings
- **Gavi**: inform Vaccine Investment Strategy (VIS)
- **IA2030:** to monitor progress in global R&D for new vaccines

Process to identify endemic pathogens for new vaccine R&D

We used robust research process with regions to create the Global pathogen priority list.

Mid 2022

1. Review the landscape

Nov 2022– May 2023

2. Synthesize Data

Nov 2022– May 2023

3. Conduct survey

May 2023 - December 2023

4. Identify pathogen priorities

July 2023 onwards

4a. Support regional R&D agendas

2024 onwards

5. Monitor and update

Process to identify regional and global priorities

World Health Organization

Step 1: Review the landscape

Mid 2022

1. Review the landscape

- Understand existing priorities
- Learn from previous prioritization exercises
- Define criteria for prioritization
- **Define pathogens in scope**

- Initial scope set by identifying pathogens through landscape review and applying screening questions

Screening questions	Rationale
Not emerging infectious diseases	WHO R&D Blueprint is identifying priorities
Human pathogens	Focus on human health
Without licensed vaccines, or where existing vaccines do not meet the needs of certain populations	Focus on the most acute needs
Have candidates in clinical development	Focus on targets with higher probability of success
Prioritized by existing roadmaps, TPPs, or VVPs, or recommended by regional advisors	Focus on pathogens of broad interest

- Scope has been updated based on regional advice, pipeline review, and new product licensures

MCDA: Multi-criteria decision analysis, PDVAC: Product Development for Vaccines Advisory Committee, IVB: WHO Headquarters Immunization, Vaccines, and Biologicals

Process to identify regional and global priorities

World Health Organization

Define pathogens in scope

PDVAC Actively supporting

Herpes simplex types 1 and 2

HIV-1

Influenza

Mycobacterium tuberculosis **(TB)**

Neisseria gonorrhoeae

Plasmodium falciparum

Respiratory syncytial virus (RSV) – *scores for "Unmet needs for prevention and treatment" updated in September 2023 due to new product licensures*

Salmonella **(non-typhoidal)**

Shigella **spp**

Streptococcus agalactiae **(group B streptococcus)**

Streptococcus pyogenes **(group A streptococcus)**

PDVAC Vaccine Value Profiles

Chikungunya virus

Cytomegalovirus

Hookworm

Intestinal pathogenic *E. coli* (InPEC)

Leishmania **spp**

Norovirus

Salmonella Paratyphi

Schistosomes

Other pathogens in scope

Chlamydia trachomatis – *added in December 2022 per regional advice*

Extra-intestinal pathogenic *E. coli* (ExPEC)

Hepatitis C virus – *added in December 2022 per regional advice*

Klebsiella pneumoniae

Mycobacterium leprae

Pseudomonas aeruginosa – *dropped in August 2023 due to lack of pipeline activity*

Staphylococcus aureus

Dengue – *added in October PDVAC meeting because epidemiology is expanding, and current vaccines do not meet public health need*

26 pathogens
The list has evolved since we began this exercise and is dynamic; recent PDVAC meeting requested that Dengue be added to the analysis

Process to identify regional and global priorities

World Health Organization

Mid 2022

1. Review the landscape

- Understand existing priorities
- Learn from previous prioritization exercises
- **Define criteria for prioritisation**
- Define pathogens in scope

- **8 criteria for prioritization** defined based on best practices and relevant precedents
- Refined by PDVAC and other experts in July 2022

Criteria	Definition
Annual deaths in children under 5	Deaths attributable to the pathogen in both sexes, < 5 years old
Annual deaths in people older than 5	Deaths attributable to the pathogen in both sexes, ≥ 5 years old
Years lost to disability (all ages)	Years of healthy life lost each year due to disability or ill-health caused by the pathogen
Social and economic burden per case	Reflects individual social and economic impact such as stigma and the costs of prevention, health care, and lost productivity.
Disruption due to outbreaks	Reflects societal impact due to outbreaks and epidemics, including social disruption; impact on healthcare systems, trade or tourism; and the cost of containment measures
Contribution to inequity	Reflects disproportionate impact on socially and economically disadvantaged groups, including women
Contribution to antimicrobial resistance (AMR)	Reflects the threat of resistance, based on current levels of resistance, contribution to antibiotic use, and designation as an AMR priority
Unmet needs for prevention and treatment	Reflects the effectiveness and suitability of alternative measures

MCDA: Multi-criteria decision analysis, PDVAC: Product Development for Vaccines Advisory Committee, IVB: WHO Headquarters Immunization, Vaccines, and Biologicals

Process to identify regional and global priorities

World Health Organization

Nov 2022– May 2023

2. Synthesize Data

- Each pathogen scored **region-by-region** as Very low, Low, Medium, High, or Very high for each of the 8 criteria

- Quantitative criteria scored using Global Burden of Diseases 2019 data

- Qualitative criteria scored based on literature searches, Vaccine Value Profiles, using a scoring rubric

- Scores reviewed by at least 2 regional experts and 1 disease expert

- Significant effort to ensure that scores were harmonised, systematic, and informed by the most recent and relevant data.

Pathogen	1 Annual deaths in children under 5	2 Annual deaths in people 5 and older	3 Annual years lived with disability (all ages)	4 Social and economic burden per case	5 Disruption due to outbreaks	6 Contribution to inequity	7 Contribution to antimicrobial resistance	8 Unmet needs for prevention & treatment
Mycobacterium tuberculosis (TB)	Very high	Very high	Very high	Very high	Very high	Very high	Very high	High
Human immunodeficiency virus 1 (HIV-1)	Very low	Low	High	Very high	High	Very high	Very high	High
Klebsiella pneumoniae	Very high	Very high	Very low	High	Low	Low	Very high	High
Staphylococcus aureus	High	Very high	Very low	High	Very low	Medium	Very high	High
Group A streptococcus (Streptococcus pyogenes)	Very low	Very high	Very high	High	Very low	High	High	High
Extra-intestinal pathogenic E. coli (ExPEC)	High	Very high	Very low	Medium	Low	Medium	Very high	Medium
Respiratory syncytial virus	High	Low	Very low	Medium	High	Medium	High	High
Shigella	Very low	Very low	Low	High	Medium	High	Very high	High
Hepatitis C virus	Very low	High	Very low	Very high				
Dengue virus	Very low	Very low	Medium	Medium				
Group B streptococcus (Streptococcus agalactiae)	High	Low	Very low	High				
Leishmania	Very low	Very low	Very low	Very high				
Influenza	Very low	Low	Very low	Low				
Plasmodium falciparum (malaria)	Low	Very low	Low	High				
Mycobacterium leprae (leprosy)	Very low	Very low	Very low	Very high				
Norovirus	Very low	Low	Very low	Medium				
Intestinal pathogenic E. coli (InPEC)	Very low	Very low	Very low	Medium				
Neisseria gonorrhoeae	Very low	Very low	Very low	Medium				
Cytomegalovirus	Very low	Low	Medium	High				
Chikungunya virus	Very low	Very low	Very low	Medium				
Chlamydia trachomatis	Very low	Very low	Very low	Very high				
Salmonella Paratyphi	Very low	Very low	Very low	Low				
Herpes simplex types 1 and 2	Very low	Very low	Very low	High				
Non-typhoidal Salmonella	Very low	Very low	Very low	Low				
Schistosomes	Very low	Very low	Very low	Low				
Hookworm	Very low	Very low	Low	Low				

ARTICLE IN PRESS

Vaccine xxx (xxxx) xxx

Contents lists available at ScienceDirect

Vaccine

journal homepage: www.elsevier.com/locate/vaccine

ELSEVIER

Value profile for respiratory syncytial virus vaccines and monoclonal antibodies

Jessica A. Fleming, Ranju Baral, Deborah Higgins, Sadaf Khan, Sonali Kochar, You Li, Justin R. Ortiz, Thomas Cherian, Daniel Feikin, Mark Jit, Ruth A. Karron, Rupali J. Limaye, Caroline Marshall, Patrick K. Munywoki, Harish Nair, Lauren C. Newhouse, Bryan O. Nyawanda, Clint Pecenka, Katie Regan, Padmini Srikantiah, Rachel Wittenauer, Heather J. Zar, Erin Sparrow

Process to identify regional and global priorities

Nov 2022– May 2023

3. Conduct survey

We carried out a multi-criteria decision analysis (MCDA) survey involving policy makers and other stakeholders to develop a top 10 pathogen list for each region, and combine to create a Global Pathogen Priority List.

Why use MCDA?

- Designed for complex decisions with diverse perspectives

- Has been used by IOM, CEPI, and WHO to define R&D priorities

- Endorsed by IVIR-AC for prioritization of health interventions and research

- Non-biased approach to value criteria to prioritize pathogens, it does not require pathogen knowledge to participate

- Results give insight into what people value

- Pathogen data can be updated as new information emerges

Process to identify regional and global priorities

Nov 2022– May 2023

3. Conduct survey

- Surveys built using the 1000minds tool, populated with pathogens scores for each of the WHO regions, and translated into the major languages for each region

- Targeted dissemination by email to policy makers, health practitioners, and others from November 2022 to April 2023

- Participants carried out the survey without any pathogen names being present, they were asked to choose between hypothetical pathogens and values for their region.

- The tool calculated weights for criteria, multiplied by pathogen scores, to calculate the list of top 10 pathogens for each region.

Discrete choices

Criteria weights

Pathogen ranks

11

Compile global priority list

World Health Organization

May 2023 - December 2023

4. Identify pathogen priorities

- The Global priority pathogen list was created by bringing together all the pathogens that were identified by regions (**17 pathogens**).

- The Global List is robust: increasing the number of responses, dividing responses into clusters, and omitting selected criteria had no effect on its composition.

- Like IA2030, **these pathogens are diverse**

  - Reflect priorities of *all* regions

  - Affect people of all ages and all income levels

Global priority pathogens for new vaccine R&D (alphabetical)

Cytomegalovirus

Dengue

Extra-intestinal pathogenic *E. coli* (ExPEC)

Hepatitis C virus

HIV-1

Influenza

Klebsiella pneumoniae

Leishmania spp

Mycobacterium tuberculosis (TB)

Norovirus

Plasmodium falciparum

Respiratory syncytial virus (RSV)

Salmonella (non-typhoidal)

Shigella spp

Staphylococcus aureus

Streptococcus agalactiae (group B streptococcus)

Streptococcus pyogenes (group A streptococcus)

What do people value?

World Health Organization

May 2023 - December 2023

4. Identify pathogen priorities

- The importance of criteria (weights) was evaluated across all regions.

- The 8 criteria have similar importance, they range from 11% to 15%

- The most important criteria were annual deaths in children under 5, contribution to AMR, and annual deaths in people 5 years and older

Criteria Weights by Cluster (1-Cluster Model)

Next steps for supporting regions in developing R&D agendas

World Health Organization

IVB can support the development of regional R&D agendas

July 2023 onwards

4a. Support regional R&D agendas

Americas

- Presentation to regional team.

European

- Presented to RITAG in December 2023

African

- Invitation to present at RITAG in June 2024
- Broader discussions regarding joint research agenda with interest from funder
- Socialization with Africa CDC

Eastern Mediterranean

- Socialization of approach but have not yet presented to regional team or RITAG

South-east Asia

- Presentation to ITAG in September 2023

Western Pacific

- Socialization of approach but have not yet presented to regional team or ITAG

Map legend:
- African Region
- Region of the Americas
- South-East Asia Region
- European Region
- Eastern Mediterranean Region
- Western Pacific Region

map from: https://apps.who.int/iris/bitstream/handle/10665/163468/9789241564946_eng.pdf;sequence=1

14

Proposal for IA2030 SP 7.2 M&E

World Health Organization

2024 onwards

5. Monitor and update

Approach	Rationale
• Compile **global pathogen list** from regional pathogen priorities	• Anchor on regional R&D priorities • Consistent with IA2030 SP7 M&E guidance [a]
• Identify key **vaccine use cases** for each pathogen	• Multiple vaccines may be needed to address a particular pathogen • Most advanced use case may not be the most important one for public health (e.g. TB vaccines)

• Monitor progress at 2 points:
  • Entry of candidates into Phase 3 trials
  • WLA licensure and policy recommendation
	• First milestone reflects investment in large-scale efficacy trials
	• Second milestone reflects success in vaccine R&D

a. IA2030 SP7 M&E: https://www.immunizationagenda2030.org/images/documents/IA2030_Annex_FrameworkForActionv04.pdf
b. GVAP Lessons Learned: https://apps.who.int/iris/rest/bitstreams/1255869/retrieve

Identify unmet "Use Cases" for each pathogen

World Health Organization

Definition

- The intended target population and outcome to be achieved by use of the vaccine or monoclonal antibody

40 unmet use cases identified for pathogens on the global list

Approach

- Compiled from existing PPCs, TPPs, published literature, developer strategies

- Focus on unmet needs

- Reviewed by IVB experts and PDVAC members

- For M&E purposes; is not WHO guidance

- Living document, will evolve as R&D progresses

Examples

- **Preventing dengue fever**: vaccine for dengue naïve and immune individuals, to prevent dengue febrile illness induced by any dengue serotype

- **Maternal group B streptococcus (GBS) vaccines**: for maternal immunization during pregnancy to prevent GBS-related stillbirth and invasive GBS disease in neonates and young infants

- **Pediatric respiratory syncytial virus (RSV) vaccines**: for active immunization of infants, to prevent RSV disease in infants and young children

16

Monitor progress in meeting the use cases

World Health Organization

a. Entry of candidates into Phase 3 trials

b. WLA licensure and policy recommendation

Policy & Prequalification

Proof-of-Effectiveness/ Implementation studies

Proof-of-Efficacy

Registration

Discovery

Preclinical

Proof-of-Concept

Indicator	Definition
SP 7.2 a	% of use cases that have vaccines or monoclonal antibodies (mAbs) in Phase 3 trials
SP 7.2 b	% of use cases that have vaccines mAbs that are licensed by a WHO-listed authority (WLA) or transitional WLA and have a policy recommendation

Figure adapted from Hutubessy R, Lauer JA, Giersing B, Sim SY, Jit M, Kaslow D, et al. The Full Value of Vaccine Assessments (FVVA): a framework for assessing and communicating the value of vaccines for investment and introduction decision-making. BMC Med 2023;21:229. https://doi.org/10.1186/s12916-023-02929-0.

17

From Analyses to Actions

World Health Organization

What can stakeholders do to accelerate progress?

Discovery → Preclinical → Proof-of-Concept → Proof-of-Efficacy → Registration → Policy & Prequalification / Proof-of-Effectiveness/ Implementation studies

Research

- **Definition**: Few candidates in development, substantial technical challenges

- **Stakeholder actions needed**: Develop tools to assess and improve feasibility, such as immunological assays, preclinical models, correlates of protection

- **IVB/PDVAC role**: Horizon scanning to evaluate progress in biological feasibility and other technical hurdles

Advance R&D

- **Definition**: Strong development pipeline with promising candidates

- **Stakeholder actions needed**: Facilitate translational research and accelerate candidates to clinical proof-of-concept, create consensus on pathway to regulatory approval

- **IVB/PDVAC role**: Provide guidance such as Preferred Product Characteristics (PPCs), Target Product Profiles (TPPs), technical R&D Roadmaps and Full Value of Vaccine Assessments (FVVA) to inform product development and clinical trial design

Prepare for Uptake

- **Definition**: Candidates have a high potential for licensure in the near future

- **Stakeholder actions needed**: Prepare for policy decisions and implementation

- **IVB/PDVAC role**: Provide guidance such as Evidence Considerations for Vaccine Policy (ECVP) and Implementation preparedness frameworks

Conclusions

- As a global health community we must focus our **efforts on developing vaccines** for the pathogens that most impact communities across the world.

- It is the right thing to do. And to do this right we need to **work together with regions and countries**. Too often decisions on the vaccines to prioritise have been taken only at a global level.

- The Priority Pathogen list is an example of how we can work to be **country led** which is a core principle of the Immunization Agenda 2030.

- Working with regions and countries has provided other valuable insights and opportunities that can support the vaccine development community: **need for combination vaccines, improving existing vaccines, or enhancing regional research capacity**.

- The overall priority pathogen list was created by bringing together **all the pathogens that were identified by regions**.

- The list is not intended to be restrictive, it is the result of a robust survey process with regions but **should be read alongside** other evidence and considerations e.g. feasibility of vaccine development, existing R&D strategies.

Contributors

World Health Organization

Strategic discussions and guidance

PDVAC Members and meeting participants

SAGE Members and meeting participants

SP7 Working Group members and meeting participants

WHO IVB and AFRO VPD

Gavi policy team

SP7 Working Group Chairs

KP Asante

David Kaslow (until Dec 2022) [c]

Methodology advice

Rob Baltussen

Paul Hansen

Maarten Jansen

Mark Jit [c]

Lydia Kapiriri

Stacey Knobler

Colin Sanderson

Yot Teerawattanon

Global Burden of Diseases data

Mohsen Naghavi

Kelly Bienhoff

Eve Wool

Translation review

Bader Al Ruwahi [c]

Enric Jané

Ibrahim Khalil

Annie Mo

Irina Morozova

Ana Paula Szylovec

Megan Williamson

Dina Youssef

Review of pathogen scores

Winston Abara

Muhammed Afolabi

Ahmed Deemas Al Suwaidi [b]

KP Asante

Helena Hervius Askling

Diana Rojas Alvarez

Alan Barrett

Lou Bourgeois

Jeffrey Cannon

Chris Chadwick

Kawser Chowdhury [b]

Hannah Clapham

Alan Cross

Ghassan Dbaibo

Carolyn Deal

David Durrheim [a]

Diana Faini

Pat Fast

Peter Figueroa [a, b]

Amadou Garba

Nebiat Gebreselassie

Birgitte Giersing

Sami Gottlieb

Michelle Groome

Bill Hausdorff

Julie Jacobson

Paul Kaye

Ruth Karron [c]

Sonali Kochhar [a]

Kirsty Le Doare

Jean C. Lee

Katharine Looker

Ben Lopman

Niklas Luhmann

Cal MacLennan

Kim Mulholland [a]

Harish Nair

Kathleen Neuzil [a]

Patricia Njuguna

Helen Rees [a, b]

Andrew Steer

Cristiana Toscano [a, b]

Anh Wartel

Survey dissemination

Sunil Bahl

Paula Barbosa

Moredreck Chibi

Siddhartha Datta

Peter Figueroa [a, b]

Adam Finn [b]

Jessica Gu

Quamrul Hasan

Louise Henaff

Benido Impouma

Gagandeep Kang [b, c]

Shaowei Li [c]

Ziad Memish [b]

Chris Morgan [b]

Nicaise Ndembi

Marc Perut

Helen Rees [a, b]

Daniel Salas

Kamel Senouci

Rajinder Suri

Yoshihiro Takashima

Ole Wichmann [b]

and many others at regional and country levels

Consultation partners

African CDC

Global NITAG Network

PAVMN, Africa

HITAP, Thailand

WHO regional offices, CEPI, WHO R&D Blueprint team members

Additional discussions in progress

Project team

WHO

Birgitte Giersing

Mateusz Hasso-Agopsowicz

Erin Sparrow

Bridges to Development

Angela Hwang

Ísis Umbelino

Alan Brooks

Anastasia Pantelias

Maria Dreher

Maria-Graciela Hollm-Delgado

[a] current or former SAGE Member

[b] RITAG or NITAG member

[c] current or former PDVAC member

PDVAC: WHO Product Development Vaccines Advisory Committee, SAGE: WHO Strategic Advisory Group of Experts on Immunization

Highlight shows SP7 WG members (prior and current)

20

Thank You